Oxford Biomedica (OXB)

Sector:

Pharma and Biotech

Index:

FTSE 250

 617.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 653.00
  • 52 Week Low: 232.50
  • Currency: UK Pounds
  • Shares Issued: 120.21m
  • Volume: 0
  • Market Cap: £741.68m
  • RiskGrade: 125

Latest ShareCast News

Oxford Biomedica acquires US viral vector facility

By Iain Gilbert

Date: Tuesday 07 Oct 2025

(Sharecast News) - Cell and gene therapy outfit Oxford Biomedica said on Tuesday that it had agreed to acquire a viral vector manufacturing site in Rockville, Maryland, from ABL for $60m in cash, expanding its US footprint and strengthening its contract development and manufacturing offering.

Oxford Biomedica reiterates outlook as interim losses narrow

By Abigail Townsend

Date: Tuesday 23 Sep 2025

(Sharecast News) - Oxford Biomedica reiterated full-year guidance on Tuesday, after the biopharma saw strong demand throughout the first half and trimmed losses.

RBC Capital Markets raises target price on OXB

By Iain Gilbert

Date: Tuesday 26 Aug 2025

(Sharecast News) - Analysts at RBC Capital Markets hiked their target price on gene and cell therapy firm OXB from 800p to 930p on Tuesday following its recent oversubscribed £60m equity funding and revenue guidance reiteration.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

OXB Market Data

Currency UK Pounds
Share Price 617.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 653.00
52 Week Low 232.50
Volume 0
Shares Issued 120.21m
Market Cap £741.68m
RiskGrade 125

OXB Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
35.16% below the market average35.16% below the market average35.16% below the market average35.16% below the market average35.16% below the market average
17.07% above the sector average17.07% above the sector average17.07% above the sector average17.07% above the sector average17.07% above the sector average
Price Trend
84.11% above the market average84.11% above the market average84.11% above the market average84.11% above the market average84.11% above the market average
86.36% above the sector average86.36% above the sector average86.36% above the sector average86.36% above the sector average86.36% above the sector average
Income Not Available
Growth
5.07% above the market average5.07% above the market average5.07% above the market average5.07% above the market average5.07% above the market average
24.14% below the sector average24.14% below the sector average24.14% below the sector average24.14% below the sector average24.14% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 4
Sell 0
Strong Sell 0
Total 10
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

OXB Key Personnel

Chair Roch Doliveux
CEO Frank Mathias
CFO Lucinda (Lucy) Crabtree

Top of Page